Standard BioTools/LAB

$2.58

2.38%
-
1D1W1MYTD1YMAX

About Standard BioTools

Standard BioTools Inc. develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines. The Company's segments include Proteomics and Genomics. The Proteomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of proteins. The Genomics segment includes its instruments, consumables, software, and services based upon technologies used in the identification of genes and their functions. The Company provides insights in health and disease using its mass cytometry and microfluidics technologies, which serve applications in proteomics and genomic. It works with academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories around the world, focusing on the needs in translational and clinical research, including oncology, immunology, and immunotherapy. The Company also provides differentiated multi-omics tools for research.

Ticker

LAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Scientific & Technical Instr.

CEO

Michael Egholm

Employees

534

Headquarters

South san francisco, United States

LAB Metrics

BasicAdvanced
$965.28M
Market cap
-
P/E ratio
-$0.94
EPS
1.63
Beta
-
Dividend rate
$965.28M
1.62737
$3.16
$1.46
2.04M
1.447
1.259
2.441
38.917
-13.8%
-20.93%
-26.63%
9.077
17.399
8.57%
61.24%
-8.35%

What the Analysts think about LAB

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
38.76% upside
High $4.00
Low $3.25
$2.58
Current price
$3.58
Average price target

LAB Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-70.1% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$28.1M
11.07%
Net income
$-19.7M
-5.74%
Profit margin
-70.1%
-15.13%

LAB Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 92.31%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.22
-$0.27
-$0.25
-
Expected
-$0.21
-$0.12
-$0.13
-$0.13
Surprise
4.76%
125%
92.31%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Standard BioTools stock?

Standard BioTools (LAB) has a market cap of $965.28M as of April 23, 2024.

What is the P/E ratio for Standard BioTools stock?

The price to earnings (P/E) ratio for Standard BioTools (LAB) stock is 0 as of April 23, 2024.

Does Standard BioTools stock pay dividends?

No, Standard BioTools (LAB) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Standard BioTools dividend payment date?

Standard BioTools (LAB) stock does not pay dividends to its shareholders.

What is the beta indicator for Standard BioTools?

Standard BioTools (LAB) has a beta rating of 1.63. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Standard BioTools stock price target?

The target price for Standard BioTools (LAB) stock is $3.58, which is 40.94% above the current price of $2.54. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Standard BioTools stock

Buy or sell Standard BioTools stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing